Related Experiment Video
Updated: May 29, 2026
12:23
Granulocyte-dependent Autoantibody-induced Skin Blistering
Published on: October 12, 2012
Corticosteroid use in autoimmune blistering diseases
1St George Hospital, Kogarah, Sydney, NSW 2217, Australia.
Dermatologic Clinics
|September 20, 2011
Summary
Corticosteroids effectively manage autoimmune blistering diseases (AIBD) but have side effects. This review examines evidence for safer corticosteroid use and strategies to minimize adverse outcomes in AIBD patients.
Area of Science:
- Immunodermatology
- Pharmacology
- Clinical Medicine
Background:
- Autoimmune blistering diseases (AIBD) often require potent immunosuppression.
- Corticosteroids are a cornerstone therapy for AIBD, offering rapid symptom control.
- However, corticosteroid use is associated with significant acute and long-term adverse effects.
Purpose of the Study:
- To review the current evidence regarding corticosteroid efficacy and safety in AIBD.
- To evaluate different corticosteroid delivery systems and regimens for potential advantages.
- To discuss methods for minimizing adverse outcomes associated with corticosteroid therapy in AIBD.
Main Methods:
- Systematic review of existing literature on corticosteroid use in AIBD.
- Analysis of evidence-based data on various corticosteroid formulations and treatment protocols.
- Evaluation of strategies for patient monitoring and adverse event prevention.
Main Results:
- Evidence supports the efficacy of corticosteroids in achieving remission for AIBD.
- Specific delivery systems or regimens may offer improved safety profiles, though data is evolving.
- Careful patient monitoring and preventive measures are crucial for mitigating side effects.
Conclusions:
- Corticosteroids remain vital for AIBD management, necessitating a balance between efficacy and safety.
- Further research into optimized corticosteroid strategies is warranted.
- Implementing evidence-based monitoring and preventive interventions is essential for patient well-being in AIBD.
Related Concept Videos
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.